You're listening to Well Now, Sleyts podcast on Health and Wellness.

I'm Mya Fella.

And I'm Kavita Patel.

Mya, for decades we have been trying to find just the right ability to intervene with the chronic disease obesity through pharmacologic interventions.

There have been many drugs that I have used over through pharmacologic interventions.

There have been many drugs that I have used over years in practice,

starting with even what has become kind of negatively

corresponded to in the public setting, like Fenn F Fen, but has actually been used in

medical settings that drugs like Cusimia and others which are still very

valid along with really severe interventions like bariatric surgery, but for many in 2021 those

efforts reached a milestone when the Food and Drug Administration approved

semi-glutide injection in the form of Wegovi specifically indicated for weight loss.

This was done for adults with obesity or classified as overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.

And there's no question that since then the impact of this approval and approval of other similar drugs have just

gone on to change the landscape of obesity medicine. A few years later just

recently drugs such as Wagovi and Manjaro are now used in treating at least

13% of American adults and there are some that have not reported the use but are

obtaining the drugs from other countries that's how popular this

drug is. By 2030 it is estimated that 30 million people in the United States that's 9%

of the entire population of adults will be using a GLP1 drug.

Today we're about to dive deeper into the world of GLP1 medications

as they continue to drastically change the medical world as well as filling up your

...